Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSS68 · 1 trial · 1 indication
The number of adverse events (AEs), serious adverse events (SAEs), and drug related adverse events following administration of SSS68.
| Arm | Type | Description |
|---|---|---|
| SSS68 | EXPERIMENTAL | SSS68 at doses ranging from 2 mg up to 1200 mg |
| Placebo | PLACEBO_COMPARATOR | Matching placebo |
| Name | Type | Description |
|---|---|---|
| SSS68 | DRUG | A single dose of SSS68 will be administered SC on Day 1. |
| Placebo | DRUG | A single dose of placebo will be administered SC on Day 1. |
Inclusion Criteria: 1. Able to understand and comply with protocol requirements, voluntarily participate in the trial and sign a written informed consent form (ICF). 2. Male or female participants aged 18-45 years (inclusive) when signing the ICF. 3. Male participants with body weight ≥ 50 kg, and ...
SSS68 is an investigational small molecule being studied for use in healthy adult participants. It is currently in a Phase 1 clinical trial that evaluates the drug following a single subcutaneous administration. The study is designed to assess the drug's effects in a controlled setting with healthy volunteers.
SSS68 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol SBFM. The company is conducting a Phase 1 clinical trial to evaluate the safety and tolerability of SSS68 in healthy adult participants.
SSS68 is currently in Phase 1 of clinical development. It is an investigational drug that has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is designed to evaluate the drug's safety, tolerability, and pharmacokinetics following a single subcutaneous administration in healthy participants.
SSS68 is being studied in a Phase 1 clinical trial registered as NCT07606976. The trial is titled 'A Study of SSS68 Following a Single Subcutaneous Administration in Healthy Adult Participants' and is planned to enroll 50 participants in China. The study is randomized, double-blind, and placebo-controlled, and it is currently not yet recruiting.
SSS68 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug is being studied in a clinical trial to evaluate its safety and tolerability in healthy participants, but it has not yet received regulatory approval for any use.